Patent ID: 11944663
Assignee: CHENGDU KANGHONG BIOTECHNOLOGIES CO. LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method for treating an angiogenic eye disorder in a human patient, said method comprising a first treatment phase comprising sequentially administering to the patient a VEGF antagonist at 4-week intervals on Day 1, Week 4 and Week 8; wherein the VEGF antagonist comprises amino acid sequence of SEQ ID NO:1, further comprising a second treatment phase, the second treatment phase comprises administering to the patient the VEGF antagonist at 8-week intervals or 12-week intervals until about 36 weeks from the initiation of the treatment, and comprising a third treatment phase, wherein the third treatment phase starts from week 40 and comprises administering the VEGF antagonist on a PRN basis; wherein upon treatment the patient has a decrease in retinal thickness by at least about 80 μm.